SCHEMBL3604028

SCHEMBL3604028

COC(=O)[C@@H](NS(=O)(=O)c1ccc(-c2ccc(NC(=O)c3cc4c(C)nn(C)c4s3)cc2)cc1)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.47
MAPT P10636 6/20 0.47
NPSR1 Q6W5P4 2/20 0.47
POLB P06746 2/20 0.47
BLM P54132 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
APEX1 P27695 1/20 0.47
PDE7A Q13946 3/20 0.44
MMP13 P45452 7/20 0.44
ADAMTS4 O75173 2/20 0.43
MMP14 P50281 2/20 0.43
TP53 P04637 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
MMP8 P22894 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604033 1.00 MMP2 (0.47) MMP2MAPTNPSR1POLBBLM
SCHEMBL3615858 0.91 MMP2 (0.54) MMP2MMP13ADAMTS4MMP14MMP1
SCHEMBL3615861 0.91 MMP2 (0.54) MMP2MMP13ADAMTS4MMP14MMP1
SCHEMBL3610846 0.89 MAPT (0.52) MMP2MAPTNPSR1POLBBLM
SCHEMBL3610850 0.89 MAPT (0.52) MMP2MAPTNPSR1POLBBLM
SCHEMBL13314504 0.83 ADAMTS4 (0.52) MMP2MMP13ADAMTS4MMP14MMP1
SCHEMBL3607252 0.81 MMP2 (0.54) MMP2MAPTNPSR1POLBBLM
SCHEMBL3607255 0.81 MMP2 (0.54) MMP2MAPTNPSR1POLBBLM
SCHEMBL3611088 0.76 MMP2 (0.54) MMP2MMP13ADAMTS4MMP14MMP1
SCHEMBL3611082 0.76 MMP2 (0.54) MMP2MMP13ADAMTS4MMP14MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP disclosed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC MMP2 5/4885MAPT 4416/4885NPSR1 2307/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC MMP2 5/4885MAPT 4416/4885NPSR1 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.